ADICON Clinical LaboratoryADICON Clinical Laboratory


LabCorp launches expanded IBD testing profile

Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today the availability of an expanded testing menu to help clinicians diagnose, treat and monitor the course of Inflammatory Bowel Disease (IBD).

“The IBD Expanded Profile helps to diagnose disease and contributes to optimizing treatment.”

Gastrointestinal (GI) tract disorders are often presented with non-specific symptoms and are difficult to diagnose, especially in primary care settings. Inflammatory Bowel Disease (IBD) is one of the most common and serious gastrointestinal disorders. The two clinically distinctive forms of IBD are ulcerative colitis and Crohn's disease. Treatments can also be complicated, involving immunosuppressant therapies, biological drugs and/or surgery.